TVTX
NASDAQTravere Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News · 26 weeks81-58%
2026-04-192026-10-11
Mix2990d
- Other11(38%)
- Insider10(34%)
- SEC Filings6(21%)
- Earnings2(7%)
Latest news
25 items- PRTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on October 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 178,580 shares of its common stock to 33 new employees, consisting of inducement stock options to purchase an aggregate of 36,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 142,580 shares of its common stock. These inducement stock options and inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan ("2018 Plan") but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering
- PRTravere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026Two-year SPARTAN data show 75% complete proteinuria remission and eGFR stabilization with first-line use of FILSPARI in IgANFILSPARI demonstrated approximately 3x higher complete proteinuria remission rates and 75% lower kidney failure rates versus maximum labeled dose irbesartan in a post hoc analysis of FSGS patients without nephrotic syndrome from the DUPLEX StudyFeatured ASN presentations reinforce FILSPARI’s growing role in transforming treatment and improving long-term outcomes in rare kidney diseaseTravere Therapeutics, Inc. (NASDAQ:TVTX) today announced that it will share nine new data presentations, including five oral presentations, at the American Society of Nephrology (ASN) Kidne
- PRTravere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental GlomerulosclerosisTravere Therapeutics, Inc. (NASDAQ:TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,120, titled "Biphenyl Sulfonamide Compounds for the Treatment of Kidney Diseases or Disorders," directed to certain methods of using FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS). Upon issuance, the patent is expected to provide U.S. patent coverage for certain methods of using sparsentan in FSGS into October 2037. The allowed application is expected to issue as a U.S. patent following payment of the issue fee and standard USPTO post-allowance processing. Travere expects to submit the i
- SECTravere Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Travere Therapeutics, Inc. (0001438533) (Filer)
- PRTravere Therapeutics Announces Planned Chief Executive Officer TransitionEric Dube, Ph.D., has decided to step down as President and Chief Executive Officer in December Following Eight Years of Exemplary LeadershipBradley L. Campbell to be Appointed President and CEO Effective December 1, 2026Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that Eric Dube, Ph.D., has made the difficult and personal decision to step down as president and chief executive officer to focus on his health and family. The Company’s Board of Directors has unanimously appointed Bradley L. Campbell, former president and CEO of Amicus Therapeutics, now a wholly owned subsidiary of BioMarin Pharmaceutical Inc., to succeed Dr. Dube as president and chief executive officer and a member
- INSIDERChief Research Officer Rote William E. exercised 191,500 shares at a strike of $21.40 and sold $13,135,397 worth of shares (209,048 units at $62.83) as part of a pre-agreed trading plan, decreasing direct ownership by 15% to 98,197 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- INSIDEREVP, CHIEF COMMERCIAL OFFICER Heerma Peter exercised 258,189 shares at a strike of $15.69 and sold $17,857,830 worth of shares (283,189 units at $63.06) as part of a pre-agreed trading plan, decreasing direct ownership by 18% to 117,066 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- INSIDEREVP, Head of R&D & CMO Inrig Jula exercised 32,395 shares at a strike of $8.93 and sold $2,785,021 worth of shares (44,674 units at $62.34) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 100,491 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- INSIDERChief Legal Officer and GC Reed Elizabeth E exercised 37,500 shares at a strike of $15.46 and sold $2,337,695 worth of shares (37,500 units at $62.34) as part of a pre-agreed trading plan (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- INSIDERCHIEF EXECUTIVE OFFICER Dube Eric M exercised 400,000 shares at a strike of $23.34 and sold $25,390,729 worth of shares (400,000 units at $63.48) as part of a pre-agreed trading plan (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Cline Christopher R. exercised 20,000 shares at a strike of $17.44 and sold $3,148,544 worth of shares (50,508 units at $62.34) as part of a pre-agreed trading plan, decreasing direct ownership by 26% to 87,508 units (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- INSIDERSVP, CHIEF ACCOUNTING OFFICER Calvin Sandra exercised 5,375 shares at a strike of $24.19 and sold $335,005 worth of shares (5,375 units at $62.33) as part of a pre-agreed trading plan (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- PRTravere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation ForumTravere Therapeutics, Inc. (NASDAQ:TVTX) today announced that company management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:30 a.m. ET.Live webcast of the presentation will be accessible on the Investor page of Travere’s website at ir.travere.com/events-and-presentations. Replay will be available for up to 30 days following the event.About Travere TherapeuticsAt Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment opt
- SECSEC Form 144 filed by Travere Therapeutics Inc.144 - Travere Therapeutics, Inc. (0001438533) (Subject)
- PRTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on September 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to 16 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 56,220 shares of its common stock. These inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan ("2018 Plan") but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4).The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the grant da
- INSIDERDirector Meckler Jeffrey A exercised 20,000 shares at a strike of $21.98 and sold $1,346,106 worth of shares (20,000 units at $67.31) as part of a pre-agreed trading plan (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Cline Christopher R. sold $42,610 worth of shares (642 units at $66.37), decreasing direct ownership by 0.54% to 118,016 units (SEC Form 4) to cover taxes4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- INSIDERDirector Lyons Gary A exercised 10,000 shares at a strike of $17.44 and sold $632,846 worth of shares (10,000 units at $63.28) as part of a pre-agreed trading plan (SEC Form 4)4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
- SECSEC Form 144 filed by Travere Therapeutics Inc.144 - Travere Therapeutics, Inc. (0001438533) (Subject)
- SECSEC Form 144 filed by Travere Therapeutics Inc.144 - Travere Therapeutics, Inc. (0001438533) (Subject)
- PRTravere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on August 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to 12 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 38,940 shares of its common stock. These inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan ("2018 Plan") but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the grant d
- SECSEC Form SCHEDULE 13G filed by Travere Therapeutics Inc.SCHEDULE 13G - Travere Therapeutics, Inc. (0001438533) (Subject)
- SECSEC Form SCHEDULE 13G filed by Travere Therapeutics Inc.SCHEDULE 13G - Travere Therapeutics, Inc. (0001438533) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Travere Therapeutics Inc.SCHEDULE 13G/A - Travere Therapeutics, Inc. (0001438533) (Subject)
- PRTravere Therapeutics to Participate at Upcoming Investor ConferencesTravere Therapeutics, Inc. (NASDAQ:TVTX) today announced that company management will participate in the following upcoming investor conferences: Canaccord Genuity's 46th Annual Growth Conference Presenting on Tuesday, August 11, 2026, at 3:00 p.m. ET Wells Fargo 21st Annual Healthcare Conference Tuesday, September 8, 2026 Citi 2026 Biopharma Back to School Conference Wednesday, September 9, 2026 2026 Cantor Global Healthcare Conference Presenting on Thursday, September 10, 2026, at 9:10 a.m. ET Live webcasts of the presentations will be accessible on the Investor page of Travere’s website at ir.travere.com/events-and-presentations. Replays will be available for up to 30 days foll
TVTX FAQ
6 questionsWhat does Travere Therapeutics Inc. do?
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the...Where does TVTX stock trade?
Travere Therapeutics Inc. (TVTX) is listed on NASDAQ.What sector and industry is TVTX in?
Travere Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about TVTX?
Travere Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Piper Sandler: Overweight with a $4900.00 price target on 2026-04-14. Recent price targets range from $2500.00 to $4900.00.What companies are similar to TVTX?
Notable peers in the same industry include MIRM (Mirum Pharmaceuticals Inc.), KDNY (Chinook Therapeutics Inc.), CALT (Calliditas Therapeutics AB), APLT (Applied Therapeutics Inc.). Compare TVTX side-by-side with any of them on Quantisnow.How can I track TVTX on Quantisnow?
Quantisnow aggregates Travere Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TVTX to receive live email and push alerts on every new disclosure.